The White House said the United States will still have enough vaccines for all Americans by the end of next month, despite problems with the The single “drug product” resulted in the loss of 15 million doses of Johnson & Johnson’s vaccine.
“We are still monitoring the number of doses required to vaccinate all adult Americans by the end of May,”; Psaki said Monday. “This is not even an FDA-approved facility.”
She continued that the United States “did not bet on these volumes” and that Johnson & Johnson “assured us that we would receive the 24 million volumes promised in April”.
CNN’s Kaitlan Collins has been pressured over whether the problem might increase vaccination hesitation across the United States. Psaki replied, “We’ve never seen that.”
“This is why the FDA approval process came about,” she said. “The process works in many ways because the FDA didn’t approve the website. Steps are being taken to resolve some of these issues, and we have several contingency plans. ”
“When all of us say here that ‘Why are we prescribing different doses? Why have we come to the point where we share doses with all countries of the world?’ Partly because we have to plan for what’s to come. This happened, ”she said.
“We have to plan to deal with situations,” Psaki added. “That’s one of the reasons we will remain in a place where we have enough vaccines for adult Americans by the end of May.”
Some background: As previously reported by CNN, a source familiar with Johnson & Johnson’s vaccine process told CNN on Saturday the loss was not a big setback.
Johnson & Johnson said, One set of “pharmaceutical products” failed quality control checks and was discarded. The US-based vaccine is currently manufactured at a facility in the Netherlands, but contract manufacturer Emergent BioSolutions is producing in quantities at its Baltimore facility. The plant is awaiting approval from the U.S. Food and Drug Administration when it receives a contamination problem.
“Once the factory was back in operation, the method of producing this vaccine, especially in these large groups, making it up for this kit should not be a major setback. It would have been a setback in just a few weeks, ”the source told CNN.
Emergent also makes a vaccine for AstraZeneca, whose vaccine is not yet licensed. In the US. Like Johnson & Johnson, AstraZeneca’s vaccine uses a virus to carry the genetic material known as the vector virus.
Emergent and Johnson & Johnson said the quality control measures were causing problems. No vaccines made at the facility were shipped to be vials or dispensed, and officials stressed that no one was at risk of contamination.
CNN reported that it has been helping produce the Covid-19 vaccine for Johnson & Johnson and AstraZeneca for months, according to a source familiar with the situation.
In addition to the 15 million doses of the drug to be discarded, Emergent has successfully produced 115 million doses of Johnson & Johnson’s vaccine, which are at various stages of the supply chain, the sources said.
The source added that it is not uncommon for the pharmaceutical industry to dispose of multiple vaccines, and the fact that Emergent and J&J detected contamination before any impacted dose “shows that the system is in good working order”.